header image
GfK Healthcare November 2010  
 
 
 
REMS: Involving Marketing Research Companies to Ensure Best Practices and Greater Efficiencies
 

 
 
 

By Rony Ben-David, Vice President

If there is a call by the Food and Drug Administration (FDA) for a REMS for one of your products, who do you trust to help in the process? While some might say a consultancy firm alone could handle every aspect of your submission, this article explores how integrating a marketing research agency into the process can bring greater efficiencies and help ensure the research is done correctly.

In today’s reality, the FDA has the authority to require the submission and implementation of a Risk Evaluation and Mitigation Strategy (REMS) if it determines one is necessary to ensure that the benefits of certain drugs and biologics outweigh their risks.

 
   
Read More
 
 
 
 
What's Happening to Your Health Plan?
 

 
 
 

When thinking about the health care reform bill, most Americans, and probably most pharmaceutical marketers and marketing researchers, focus on the bill’s provision of health care coverage for tens of millions of people who are currently without any, or adequate, health insurance. While this is a consequence of the legislation, other aspects of reform deserve special consideration as well – especially by those in our profession.

This month’s published article for The Orange Pages discusses two recent Wall Street Journal articles about health care that pharmaceutical marketers and marketing researchers should read.

 
   
Read More
 
 
 
 
Did You Miss the October Issue of Pipeline?
 

 
 
 

Click here to read the issue, which includes:

  • Designing Better Medical Devices 
  • "Time" as a Construct in Health Care Marketing Research
  • Vanderveer's Views: On the Other Hand…

Pipeline archive is available. Skim the directory and select articles you missed. Access subscriber opt-in/comment form.

 
 
 
 
 
   
 
 

Books Old and New – Remembrances and Insights

I spend much of my time now studying, not just reading, books I think might be relevant to the pharmaceutical industry and channeling my learnings in the form of industry presentations, discussions and articles. In fact, I have become obsessed with the notion that someone has to wring every ounce of meaning out of these seminal works, since they are available at little or no cost and can sometimes provide better general insights than marketing research.

I don’t throw the word seminal around lightly. In order to be rated as seminal, a book has to change, fundamentally, the way I view an issue or introduce me to issues I haven’t thought about before. 

As you know, I pride myself on sharing with you almost exclusively recent seminal books, since in this rapidly changing world even the most profound wisdom often has a limited shelf life. If it was published in the last year, has been identified for me as potentially useful, and especially if it is available “e” for reading on my iPad, I will be all over it. Usually, a quick skim will reveal the extent to which the book is worthy of in-depth study.

Recently, however, my entire business library passed through my hands as I emptied my office shelves and transported books and magazines to my home study...

 
   
Read More
 
 
 
 
Contact   |  GfK Healthcare
 
  Copyright © 2010 GfK Healthcare  
 
  Published by GfK Healthcare, 587 Skippack Pike, Blue Bell PA 19422.
Reproduction or any other form of duplication only with the written permission of the publisher. All rights reserved.